#sNDA

Lead report

Celcuity Targets Q3 2026 for REVTORPYK Launch and sNDA Submission, Accelerating Commercialization

Celcuity plans to ship REVTORPYK and file its sNDA by Q3 2026, backed by positive clinical data and commercial readiness. The market watches its execution as it transitions from clinical to commercial stage.